The U.S. Preventive Services Task Force (USPSTF) updated its 2009 recommendation on breast cancer screening. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years (B recommendation). For women aged 40 to 49 years, the decision to start screening should be individualized, as the benefits may be smaller and the harms greater. The USPSTF concludes that there is insufficient evidence to assess the balance of benefits and harms of screening mammography in women aged 75 years or older, or of digital breast tomosynthesis (DBT) as a primary screening method. The USPSTF also concludes that there is insufficient evidence to assess the balance of benefits and harms of adjunctive screening for breast cancer in women with dense breasts. The USPSTF found adequate evidence that mammography screening reduces breast cancer mortality in women aged 40 to 74 years, with the greatest benefit in women aged 60 to 69 years. Screening mammography also has harms, including overdiagnosis, false-positive and false-negative results, and radiation-induced breast cancer. The USPSTF concludes that the net benefit of screening mammography in women aged 50 to 74 years is moderate. For women aged 40 to 49 years, the net benefit is small. The USPSTF concludes that the evidence on screening mammography in women aged 75 years or older is insufficient. The USPSTF found that the balance of benefits and harms of screening mammography improves with age. Women in their 60s benefit the most, while women in their 40s benefit the least. The USPSTF also found that the balance of benefits and harms of adjunctive screening in women with dense breasts is insufficient to determine. The USPSTF concludes that the evidence on DBT as a primary screening method is insufficient. The USPSTF also concludes that the evidence on adjunctive screening in women with dense breasts is insufficient. The USPSTF recommends that women aged 40 years or older without preexisting breast cancer or a high-risk lesion and not at high risk for breast cancer due to genetic mutations or a history of chest radiation should consider screening. The USPSTF emphasizes that clinical decisions involve more than evidence alone and that individualized decision-making is necessary. The USPSTF also notes that policy and coverage decisions involve considerations beyond clinical evidence. The USPSTF concludes that the evidence on screening mammography in women aged 75 years or older is insufficient. The USPSTF also concludes that the evidence on DBT as a primary screening method is insufficient. The USPSTF concludes that the evidence on adjunctive screening in women with dense breasts is insufficient.The U.S. Preventive Services Task Force (USPSTF) updated its 2009 recommendation on breast cancer screening. The USPSTF recommends biennial screening mammography for women aged 50 to 74 years (B recommendation). For women aged 40 to 49 years, the decision to start screening should be individualized, as the benefits may be smaller and the harms greater. The USPSTF concludes that there is insufficient evidence to assess the balance of benefits and harms of screening mammography in women aged 75 years or older, or of digital breast tomosynthesis (DBT) as a primary screening method. The USPSTF also concludes that there is insufficient evidence to assess the balance of benefits and harms of adjunctive screening for breast cancer in women with dense breasts. The USPSTF found adequate evidence that mammography screening reduces breast cancer mortality in women aged 40 to 74 years, with the greatest benefit in women aged 60 to 69 years. Screening mammography also has harms, including overdiagnosis, false-positive and false-negative results, and radiation-induced breast cancer. The USPSTF concludes that the net benefit of screening mammography in women aged 50 to 74 years is moderate. For women aged 40 to 49 years, the net benefit is small. The USPSTF concludes that the evidence on screening mammography in women aged 75 years or older is insufficient. The USPSTF found that the balance of benefits and harms of screening mammography improves with age. Women in their 60s benefit the most, while women in their 40s benefit the least. The USPSTF also found that the balance of benefits and harms of adjunctive screening in women with dense breasts is insufficient to determine. The USPSTF concludes that the evidence on DBT as a primary screening method is insufficient. The USPSTF also concludes that the evidence on adjunctive screening in women with dense breasts is insufficient. The USPSTF recommends that women aged 40 years or older without preexisting breast cancer or a high-risk lesion and not at high risk for breast cancer due to genetic mutations or a history of chest radiation should consider screening. The USPSTF emphasizes that clinical decisions involve more than evidence alone and that individualized decision-making is necessary. The USPSTF also notes that policy and coverage decisions involve considerations beyond clinical evidence. The USPSTF concludes that the evidence on screening mammography in women aged 75 years or older is insufficient. The USPSTF also concludes that the evidence on DBT as a primary screening method is insufficient. The USPSTF concludes that the evidence on adjunctive screening in women with dense breasts is insufficient.